Figure 1.
Allelic distribution of the ABCB1 and CYP2C19 polymorphisms in CAD patients treated with clopidogrel
| Allele | Patients with positive outcome (N=52) | Patients with negative outcome (N=44) |
|---|---|---|
| number of patients | ||
| CYP2C19*1/ ABCB1 C | 36 | 34 |
| CYP2C19*1/ ABCB1 T | 37 | 28 |
| CYP2C19*2/ ABCB1 C | 11 | 14 |
| CYP2C19*2/ ABCB1 T | 11 | 16 |
Phenotype frequencies of CYP2C19 and ABCB1 in clopidogrel treated patients
| Phenotype/Metabolizer | Patients with positive outcome (N=52) | Patients with negative outcome (N=44) | OR | p | ||||
|---|---|---|---|---|---|---|---|---|
| N | Observed Frequency (%) | HWE Frequency (%) | N | Observed Frequency (%) | HWE Frequency (%) | |||
| Normal* | 9 | 0.1731 | 0.1872 | 2 | 0.0454 | 0.1673 | 1.000 | |
| Intermediate** | 27 | 0.5192 | 0.4909 | 32 | 0.7272 | 0.4834 | 5.333 | 0.02805 |
| Poor*** | 16 | 0.3077 | 0.3218 | 10 | 0.2272 | 0.3491 | 2.812 | 0.22842 |
Demographic and clinical characteristics of the patients with coronary artery disease treated with clopidogrel_
| Parameter | Total number of patients (N=96) | Patients with positive outcome (N=52) | Patients with negative outcome (N=44) |
|---|---|---|---|
| Demographic characteristics | |||
| Age | 60.42±9.05 | 60.64±9.19 | 60.16±9.22 |
| Male | 59 (61.46%) | 33 (63.46%) | 26 (59.09%) |
| Clinical characteristics | |||
| History of myocardial infarction | 27 (28.13%) | 10 (19.23%) | 17 (38.64%) |
| History of diabetes | 48 (50%) | 24 (46.15) | 24 (54.54%) |
| NYHA classification* | |||
| Class I | 22 (22.92%) | 15 (28.85%) | 7 (15.91%) |
| Class II | 31 (32.29%) | 14 (26.92%) | 17 (38.64%) |
| Class III | 41 (42.71%) | 22 (42.31%) | 19 (43.18%) |
| Class IV | 2 (2.08) | 1 (1.92%) | 1 (2.27%) |
| Diagnosis** | |||
| 105–06 | 4 (4.17%) | 3 (5.77%) | 1 (2.27%) |
| 120–23 | 54 (56.25%) | 32 (61.54%) | 22 (50%) |
| 125 | 17 (17.71%) | 8 (15.38%) | 9 (20.45%) |
| 135 | 3 (3.13%) | 1 (1.92%) | 3 (6.82%) |
| 165–66, 170–74 | 17 (17.71%) | 8 (15.38%) | 9 (20.45%) |
Genotype frequencies of ABCB1 and CYP2C19 in patients treated with clopidogrel
| CYP2C19 | ABCB1 | Positive outcome N=52 | Observed Frequency (%) | HWE Frequency (%) | Negative outcome N=44 | Frequencies (%) | Expected Frequencies (%) | OR | 95% | p value |
|---|---|---|---|---|---|---|---|---|---|---|
| Genotype | ||||||||||
| ABCB1 CC homozygotes | ||||||||||
| *1/*1 | CC | 9 | 17.31 | 17.7 | 11 | 4.84 | 5.4 | 1.00 | ||
| *1/*2 | CC | 3 | 5.77 | 5.0 | 2 | 4.55 | 3.4 | 0.545 | 0.074–4.008 | 0.54819 |
| *2/*2 | CC | 0 | 0 | 0.4 | 0 | 0 | 0.6 | 0.826 | 0.015–45.693 | 1.0000 |
| ABCB1 CT heterozygotes | ||||||||||
| *1/*1 | CT | 19 | 36.54 | 32.9 | 11 | 25 | 11.1 | 1.00 | ||
| *1/*2 | CT | 5 | 9.62 | 16.8 | 10 | 22.73 | 9.7 | 3.455 | 0.936–12.743 | 0.05722 |
| *2/*2 | CT | 3 | 5.77 | 2.2 | 2 | 4.55 | 2.1 | 1.152 | 0.166–7.990 | 0.88644 |
| ABCB1 TT homozygotes | ||||||||||
| *1/*1 | TT | 10 | 19.23 | 19.6 | 4 | 9.09 | 8.6 | 1.00 | ||
| *1/*2 | TT | 3 | 5.77 | 5.1 | 3 | 6.82 | 7.8 | 2.500 | 0.346–18.039 | 0.35720 |
| *2/*2 | TT | 0 | 0 | 0.3 | 1 | 2.27 | 1.8 | 7.00 | 0.237–206.784 | 0.14323 |